Hudec Miroslav, Januska Jaroslav, Jiravsky Otakar, Miklik Roman, Urban Martin, Dorda Miloslav, Konecna Alica Cesnakova, Gajdusek Libor, Ranic Ivan, Vician David, Spacek Radim, Godula Bogna Jiravska, Sknouril Libor, Kala Petr
AGEL Hospital Trinec-Podlesi, Konska 453, Trinec, 739 61, Czech Republic.
Faculty of Medicine, Masaryk University, Kamenice 5, Brno, 601 77, Czech Republic.
Clin Res Cardiol. 2025 Sep 8. doi: 10.1007/s00392-025-02747-9.
Pulmonary hypertension (PH) often coexists in patients undergoing transcatheter edge-to-edge mitral valve repair procedure (M-TEER). Its pre-procedural severity is considered a negative prognostic marker. Whether the post-procedural PH resulting from M-TEER can also serve as a long-term prognostic marker is unknown.
To evaluate the influence of residual mitral regurgitation (MR) and the role of PH dynamics on long-term outcome after M-TEER.
A total of 226 patients from a single-centre prospective registry who underwent M-TEER with MitraClips between 2010 and 2022 were analysed. Patients were categorised into four phenotype groups based on a combination of post-procedural MR severity (≤ 2.5 vs. ≥ 3) and change in PH (stable/improved vs. worsened). Primary endpoints were survival, time to first heart failure hospitalisation (HFH) and a composite of both.
Overall, 86.3% of patients had severe MR and 59.7% had PH at baseline, while 75.7% had MR ≤ 2.5 and 57.5% had no residual PH after M-TEER on discharge echocardiography. Baseline PH severity did not significantly influence outcomes, but its dynamics did (stable/improved vs. worsening; median survival 63 vs. 38 months, time to HFH 74 vs. 44 months, and time to composite endpoint 49 vs. 26 months, all p < 0.05). Patients who achieved mild/moderate MR with stable/improved PH (81.0%) showed the best results across all endpoints (median survival 58 months, p = 0.027; time to HFH 74 months, p = 0.004; time to composite endpoint 50 months, p = 0.008). The groups with worsening PH after M-TEER had the worst outcomes, regardless of the degree of MR.
Assessment of pH dynamics shortly after M-TEER proved to be a valuable predictor of long-term outcome. Its combination with the post-procedural level of MR can easily identify patients at low or high risk of subsequent adverse outcomes.
肺动脉高压(PH)常并存于接受经导管二尖瓣缘对缘修复术(M-TEER)的患者中。其术前严重程度被视为不良预后指标。M-TEER术后发生的PH是否也可作为长期预后指标尚不清楚。
评估残余二尖瓣反流(MR)的影响以及PH动态变化在M-TEER术后长期结局中的作用。
分析了2010年至2022年间在单中心前瞻性注册研究中接受MitraClip M-TEER治疗的226例患者。根据术后MR严重程度(≤2.5 vs.≥3)和PH变化(稳定/改善vs.恶化)的组合将患者分为四个表型组。主要终点为生存率、首次因心力衰竭住院(HFH)的时间以及两者的复合终点。
总体而言,86.3%的患者基线时有严重MR,59.7%有PH,而在出院超声心动图检查时,75.7%的患者MR≤2.5,57.5%的患者M-TEER术后无残余PH。基线PH严重程度对结局无显著影响,但其动态变化有影响(稳定/改善vs.恶化;中位生存期63个月vs.38个月,HFH时间74个月vs.44个月,复合终点时间49个月vs.26个月,均p<0.05)。实现轻度/中度MR且PH稳定/改善的患者(81.0%)在所有终点方面表现最佳(中位生存期58个月,p=0.027;HFH时间74个月,p=0.004;复合终点时间50个月,p=0.008)。M-TEER术后PH恶化的组结局最差,无论MR程度如何。
M-TEER术后不久对PH动态变化的评估被证明是长期结局的有价值预测指标。将其与术后MR水平相结合可轻松识别后续不良结局风险低或高的患者。